



Scientific Program

- 10:30-10:50 Hemodynamic Effect of Vasoactive Agents in Patients with Cirrhosis
Soon Koo Baik, Korea
- 10:50-11:10 Clinical Staging System for Hepatocellular Carcinoma
Ho-Byung Chung, Korea
- 11:10-11:30 Living Donor Liver Transplantation
Kyung-Suk Suh, Korea

Iron Symposium

March 30th 9:00-12:00 Room B-2

Moderators: L Powell (Australia), G Ramm (Australia)

- 9:00-9:20 Intestinal Iron Absorption
Surjit KS Srail, UK
- 9:20-9:40 Pathways of Hepatic Iron Metabolism
Gregory Anderson, Australia
- 9:40-10:00 Iron Overload in the Asian-Pacific Region: Results of the "HEIRS" Study
Paul Adams, Canada
- 10:00-10:20 Non-HFE in the Asia-Pacific Region
Nathan Subramaniam, Australia

Moderators: P Adams (Canada), D Crawford (Australia)

- 10:20-10:40 Effect of Phlebotomy on HCV Hepatitis and NASH
Yoshiro Niitsu, Japan
- 10:40-11:00 Iron and Alcoholic Liver Disease
Darrell Crawford, Australia
- 11:00-11:20 Role of Iron in HCC Formation
Yves Deugnier, France
- 11:20-11:40 Non-Invasive Measurement of Iron, Hepatic Fat and Fibrosis
Tim S Pierre, Australia
- 11:40-12:00 Discussion

NASH

March 30th 13:30-16:00 Annex

Moderators: SK Sarin (India), CI Smith (USA)

- 13:30-13:45 Spectrum of Histopathological Lesions
Puja Sakhuja, India
- 13:45-14:00 The Prevalence of NAFLD-West
Coleman I Smith, USA
- 14:00-14:15 The Prevalence of NAFLD-East
Etsuko Hashimoto, Japan
- 14:15-14:30 Natural History in Asia
Henry Chan, Hong Kong
- 14:30-14:45 Insulin Resistance and Metabolomics in NASH
Shuichi Kaneko, Japan
- 14:45-15:00 Current and Novel Therapies
Shiv K Sarin, India

APASL-China

March 30th 13:30-16:00 Room B-1

Moderators: J Jia (Beijing), G Lau (Hong Kong)

- 13:30-13:45 Prevalence and Prevention of HBV in China
Hui Zhuang, Beijing

- 13:45-14:00 Efficacy of Prolonged Viral Suppression in Chronic HBV
Joseph Sung, Hong Kong
- 14:00-14:15 Chinese Guideline on the Management of CHB
Jin-Lin Hou, Guangzhou
- 14:15-14:30 Chronic Hepatitis C in China
Lai Wei, Beijing
- 14:30-14:45 HCV Patients with Persistently Normal ALT
Chee-Kin Hui, Hong Kong
- 14:45-15:00 The Role Herbal Medicine the Therapy of Liver Fibrosis
Bao-En Wang, Beijing
- 15:00-15:15 Prevalence and Management of HCC in China
Ye S Feng, Beijing
- 15:15-15:30 Studies in Japan
Run-Xuan Shao, Japan

APASL-US-JAPAN

March 30th 13:30-16:00 Room B-2

Moderators: C Walker (USA), S Mishiro (Japan)

- 13:30-13:50 What is the USJCMSP Hepatitis Panel? - A Prehistory for Future
Shunji Mishiro, Japan
- 13:50-14:00 Regional Versus Global Problems-Similar but Distinct
Rajen Koshy, USA
- 14:00-14:15 Recent Topics on HEV
Tian Cheng Li, Japan
- 14:15-14:30 HCV Host Cell Interactions and Immune Evasion
Young Hahn, USA
- 14:30-14:40 Prevalence of 2k/1b Natural Recombinant HCV Strain in Asia
Fuat Kurbanov, Japan
- 14:40-14:55 HBV Antiviral Agents / Glucosidase Inhibitors
Anand Mehta, USA
- 14:55-15:10 Antiviral Drug-resistant HBV
Anna Lok, USA
- 15:10-15:20 Designing Combination Therapy with Immune Modulators
Fazle Akbar, Japan
- 15:20-15:30 Molecular Epidemiological and Virological Studies on Hepatitis Virus Infections in Mongolia
Bira Tsatsralt-Od, Japan
- 15:30-15:40 Epidemiology of HBV/HCV/HEV/HIV Infections in Sangihe-Talaud Archipelago, an Outlier of Indonesia
Wenny Astuti, Japan
- 15:40-16:00 What Do You Want US to Do? – A Dialogue with the Audience
Christopher Walker, USA

Sponsored Seminars

Luncheon Seminar (Eisai Co., Ltd.)
March 27th 12:00-13:30 Room A

How to Monitor & How to Treat HCC

Moderator: M Omata (Japan)

Ryosuke Tateishi, Japan
Kwang Hyub Han, Korea
Leonard B Seeff, USA

Luncheon Seminar (Otsuka Pharmaceutical Co., Ltd.)
March 27th 12:00-13:30 Room B-1

BCCA Supplementation in Hepatocellular Carcinoma

Moderator: M Makuuchi (Japan)

Ronnie TP Poon, Hong Kong

Luncheon Seminar (Abbott Molecular)

March 27th 12:00-13:30 Room B-2

Moderator: M Mizokami (Japan)

Introduction

Masashi Mizokami, Japan

How Improvements in Molecular Testing are Changing Clinical Hepatitis C Management?

Vincent Thibault, France

Clinical Implication of HBV Viral Load and Genotypes
Jia-Horng Kao, Taiwan

Q&A Session

Masashi Mizokami, Japan

Satellite Seminar (Roche)

March 27th 16:00-17:30 Room A

Moderator: G Lau (Hong Kong)

Introduction

Clinical Strategies for CHB: Matching the Treatment to the Patient

Patrick Marcellin, France

Achieving Durable Responses without Resistance in HBeAg-negative CHB

Teerha Piratvisuth, Thailand

Optimising Responses in Treatment-naive and Resistant HBeAg-positive CHB Patients

Jidong Jia, China

Q&A, Chairman's Summary

Breakfast Seminar (Novartis Pharma)

March 28th 8:00-9:15 Annex

Moderator: YF Liaw (Taiwan)

Introduction

The Changing Landscape of Hepatitis B Management

Seng Gee Lim, Singapore

The Role of Viral Suppression

George Lau, Hong Kong

Road Map to Optimal Management
Edward Gane, New Zealand

Novartis: Committed to Hepatitis Research
Nikolai Naoumov, Switzerland

Q&A

Closing Remarks

Luncheon Seminar (Bristol-Myers Squibb)

March 28th 12:30-14:00 Annex

Why Risk Failure in Chronic Hepatitis B Therapy?
Three Conjectures on Getting it Right from the Start

Moderators: SK Sarin (India), DJ Suh (Korea)

Welcome Address and Introductions

Conjecture 1 - How should We Respond to Viral Load as a Call-to-action?

Dong Jin Suh, Korea

How Has Our Decision-making Evolved in Line with New Evidence?

Stephen Locarnini, Australia

Viral Load as a Driver of Disease Progression

Yun-Fan Liaw, Taiwan

Conjecture 2 - In This Era of Potent Viral Suppressors, Has Resistance Become a Secondary Issue in Treatment Success?

Shiv K Sarin, India

Mechanisms of Viral Resistance and the Naive Monotherapeutic Environment

Stephen Locarnini, Australia

Resistance Outcomes in the Therapeutic Salvage Environment

Yun-Fan Liaw, Taiwan

Conjecture 3 - Is the Lowest-risk Therapeutic Strategy in CHB the One with the Most Potent Response and Least Resistance from Day One?

Dong-Jin Suh, Korea

A Comparison of Outcomes with Current Therapeutic Options

Masao Omata, Japan

Challenge from the Floor

Audience and Faculty

Concluding Remarks and Close

Satellite Seminar (GlaxoSmithKline)

March 28th 16:00-17:30 Annex

Chronic Hepatitis B: Theory Meets Practice in Reducing Disease Progression

Moderator: JD Jia (China)

Introduction

Reducing Disease Progression in CHB: From Mechanisms to Treatment

Michael Manns, Germany

Case Studies

Hie-Won Hann, USA and Discussion Panel

Management Issues: Does Theory Meet Practice?

Joseph Sung, Hong Kong

Case Studies

Hie-Won Hann, USA and Discussion Panel

Conclusions